Tower Research Capital (TRC)’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-8,395
| Closed | -$6.13K | – | 6360 |
|
|
2023
Q4 | $6.13K | Buy |
8,395
+802
| +11% | +$680 | ﹤0.01% | 4779 |
|
|
2023
Q3 | $8.5K | Buy |
7,593
+202
| +3% | +$251 | ﹤0.01% | 4337 |
|
|
2023
Q2 | $9.98K | Buy |
7,391
+5,607
| +314% | +$7.13K | ﹤0.01% | 4190 |
|
|
2023
Q1 | $2K | Sell |
1,784
-3,363
| -65% | -$6.38K | ﹤0.01% | 5473 |
|
|
2022
Q4 | $12K | Buy |
5,147
+3,395
| +194% | +$8.51K | ﹤0.01% | 3783 |
|
|
2022
Q3 | $7K | Buy |
1,752
+856
| +96% | +$4.69K | ﹤0.01% | 4982 |
|
|
2022
Q2 | $4K | Buy |
896
+498
| +125% | +$2.62K | ﹤0.01% | 5339 |
|
|
2022
Q1 | $3K | Buy |
+398
| New | +$3.79K | ﹤0.01% | 5499 |
|
|
2021
Q4 | – | Sell |
-438
| Closed | -$8K | – | 7115 |
|
|
2021
Q3 | $8K | Buy |
+438
| New | +$7.22K | ﹤0.01% | 4618 |
|
|
2021
Q2 | – | Sell |
-10
| Closed | – | – | 6345 |
|
|
2021
Q1 | $0 | Sell |
10
-1,821
| -99% | -$54.6K | ﹤0.01% | 6060 |
|
|
2020
Q4 | $37K | Buy |
+1,831
| New | +$35.8K | ﹤0.01% | 3411 |
|
|
2017
Q2 | – | Hold |
0
| – | -$13K | – | 3920 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 1621 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 2908 |
|
|
2016
Q3 | – | Hold |
0
| – | -$28K | – | 5041 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 1992 |
|
|
2016
Q1 | – | Hold |
0
| – | -$5K | – | 5446 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3088 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 2274 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 1404 |
|
Other funds holding NVIV
Tower Research Capital (TRC)'s NVIV Position: Q1 2024 in Review
Tower Research Capital (TRC) sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 8,395 shares — an estimated $6.13K sold.
Tower Research Capital (TRC) first reported a position in NVIV in Q4 2020 and held it in 11 quarters. The position peaked at $37K in Q4 2020. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.
- Tower Research Capital (TRC) reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 8,395 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $6.13K.
- Tower Research Capital (TRC) first reported a position in InVivo Therapeutics Holdings Corp in Q4 2020 and held it in 11 quarters.
- Tower Research Capital (TRC)'s InVivo Therapeutics Holdings Corp position peaked at $37K in Q4 2020.
- 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.